Format

Send to

Choose Destination

See 1 citation:

Stat Methods Med Res. 2016 Aug;25(4):1303-12. doi: 10.1177/0962280213480282. Epub 2013 Mar 15.

Simulating the contribution of a biospecimen and clinical data repository in a phase II clinical trial: A value of information analysis.

Author information

1
Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA Department of Economics, University of South Florida, Tampa, FL, USA Benjamin.craig@moffitt.org.
2
Program of Applied Translational Research, Department of Internal Medicine, Yale University School of Medicine, USA.
3
Department of Economics, University of South Florida, Tampa, FL, USA.
4
Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA Department of Biomedical Informatics, Moffitt Cancer Center, Tampa, FL, USA.

Abstract

The potential contributions of a centralized data warehouse or repository in clinical research include the expedited accrual of subjects for phase II trials. Understanding the contribution of data warehouses that integrate clinical, biospecimen, and molecular data for the conduct of clinical trials is essential to inform private and public decisions on resource allocation and investment. We conducted a value of information analysis using data from recent trials at the Moffitt Cancer Center and simulated the potential reductions in trial size due to possible alternative scenarios of expedited accrual. In this study, we compared alternative data sets using a single model to assess value of information. Our findings suggest that the reductions in trial size range from 0% to 43%, depending on the amount of censoring in overall survival. The ability to expedite the accrual of patients for clinical trial studies using large data repositories that store data on inclusion/exclusion criteria and response to standard of care therapies demonstrated significant improvement in reducing the number of subjects needed to achieve similar end-results, as evaluated using value of information analysis with a limited number of parameters and a parsimonious model of overall survival.

KEYWORDS:

biorepository; clinical trials; neoplasms; phase II; value of information

PMID:
23503303
PMCID:
PMC3752320
DOI:
10.1177/0962280213480282
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center